Veraxa Biotech Holding AG (VRXA) Non-Current Deferred Tax Liability (2024 - 2025)
Veraxa Biotech Holding AG (VRXA) posted Non-Current Deferred Tax Liability of $2.1 million for Q4 2025, up 28.57% on a QoQ basis from $1.6 million in Q4 2024, and up 28.57% YoY from $1.6 million in Q4 2024.
Veraxa Biotech Holding AG (VRXA) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXA) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 28.57% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at $2.1 million (up 28.57% YoY), and the FY2025 full-year result was $2.1 million, up 28.57% from the prior year.
- Non-Current Deferred Tax Liability climbed to $2.1 million in Q4 2025 per VRXA's latest filing, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.1 million in Q4 2025 to a low of $1.6 million in Q4 2024.
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.05 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |